Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Glucagon

August 07, 2019

Xeris Q2 ’19 Earnings Update

Here is a brief preview of this blast: Yesterday, Xeris published its Q2 ’19 earnings press release highlighting the September 10, 2019 PDUFA for its hypoglycemia rescue product ‘Gvoke.’ Gvoke launch is anticipated in Q4 ’19. Furthermore, the company disclosed utilizing the additional data from the fourth Ph3 trial to file an MAA to EMA by YE 2019. Below, FENIX provides additional thoughts on Gvoke in the context of its additional Ph3 data, and other novel glucagon rescue products.